Almost all current therapeutic concepts in autoimmune diseases are based on the systemic suppression of immune functions and are not curative. The recent introduction of biologicals such as tumour necrosis factor blocking antibodies or receptors has added greater specificity to efficient management of disease by targeted suppression of rheumatic inflammation. It is evident, however, that only the elimination of the cells secreting inflammatory mediators, rather than the blockade of secreted molecules, will offer real specific therapeutic advantages in the future. Merely the elimination of such cells and also cells controlling the secreting effector cells could be curative and induce true long term remissions. We review here the state of the art and future therapeutic concepts that are based on the specific modulation of pathogenic cells that induce and sustain autoimmune inflammation. This sounds visionary, however, a variety of basic tools are at hand now. Thus, direct and specific cell therapy of rheumatic diseases will become a true alternative to conventional therapies. The specific targeting of autoreactive cells has to be combined with a therapeutic resetting of either central or peripheral tolerance. The latter might be possible in the nearby future with the use of regulatory T cells that have been shown to have the potential to modulate autoimmune inflammation in vivo.

**TARGETING ANTIGEN PRESENTING CELLS AND THEIR POTENTIAL TO ACTIVATE T CELLS**

Lymphocytes and, in particular, those specific for autoantigens are not the only “hot” target candidate cells for specific cellular therapies in autoimmune diseases. Autoimmune reactions are in motion with the uptake, processing, and presentation of autoantigens through APCs. The fact that at least during the primary initiation of autoimmunity professional APCs are essential implies that dendritic cells might play an important role here. Therefore it has been envisaged that blocking important costimulatory pathways such as CD80/86 could efficiently block primary activation of autoreactive T cells. While a reagent such as soluble CTLA4-Ig is highly efficient in modulating activation of autoreactive T cells in vitro or in vivo experimental models of autoimmunity the routine clinical use of such drugs most likely will be hampered due to their strong systemic side effects (fig 3) and the protective immune responses necessary to shield the body against pathogens would be altered drastically. Moreover, once established, the “reactivation” of autoreactive memory or effector T cells is less dependent on signals mediated by costimulatory molecules and thus nonprofessional APCs such as B cells or non-classical Tregs present at the site of inflammation also efficiently activate specific T cells.

However, recently, pilot short clinical trials have shown significant disease improvement in rheumatoid arthritis (RA) and that CTLA4-Ig may be surprisingly well tolerated. Doublet and Yee, data from experimental studies suggest that only acute autoimmune reactions represent targets for therapies blocking the costimulatory pathways for T cells provided by APCs. Numerous other strategies envisage the molecular “targeting” of APCs (and other cell types) such as modulating cell cycling, the proteasome, or the nuclear factor (NF)-κB pathways. Doubtless at present most of these approaches lack specificity for the cells they aim to target. Moreover, as mentioned above, already established autoreactive memory T and B cells may not be influenced as much as necessary.

**TARGETING T CELLS IN AUTOIMMUNITY**

T cells have been the target of many routine immunosuppressive treatments since a long time. Classically, various immunosuppressive drugs that interfere with intracellular signalling pathways essential for the activation and proliferation of T cells are used. However, the precise mechanisms by which T cells are activated in autoimmune diseases remain largely unknown. Most autoimmune diseases are characterized by autoreactive T cells that are activated by dendritic cells and their major histocompatibility complexes in the context of antigen presentation. These activated T cells produce a variety of cytokines that are involved in the pathogenesis of autoimmune diseases. Therefore, targeting autoreactive T cells has been proposed as a potential treatment for autoimmune diseases. This approach aims to eliminate or inactivate autoreactive T cells in the periphery or in inflamed tissues. Various methods have been developed for targeting autoreactive T cells, including adoptive transfer of regulatory T cells, blockade of costimulatory molecules, and genetic modification of T cells. These methods have shown promising results in preclinical models and some clinical trials. However, further research is needed to optimize these approaches and to overcome potential limitations such as the generation of alloreactive regulatory T cells or the development of immune evasion strategies by autoreactive T cells. Nevertheless, targeting autoreactive T cells represents a promising strategy for the treatment of autoimmune diseases.
proliferation of T cells have been regularly used in routine treatment for autoimmune diseases. The aim has been to interfere with Th cells that orchestrate autoimmune responses by distinctively instructing B cells and other T cells which differentiation pathways they have to enter. For instance, humoral autoimmunity is strictly in need of autoreactive Th cells since autoantibody producing B cells undergo T cell dependent affinity maturation. Moreover, autoreactive T cells and, in particular, Th cells exert important direct pathogenic functions such as secretion of various inflammatory mediators at sites of inflammation. T cell directed therapies in autoimmune diseases have therefore been envisaged and evaluated for a long time.

It has been evident, not only since naturally occurring regulatory CD25++ Th cells (Treg) gained the interest of clinical immunologists but also particularly from experimental models and from clinical experience, that depleting the pathogenic Th cells or modulating their function would be a key for inducing long term cure of autoimmunity. Most previous efforts, however, were based on the in vivo application of monoclonal antibody targeted T cells systemically (for example using anti-CD4 antibodies). Early studies with in vivo depleting anti-CD4 antibodies were mainly limited by the induction of long term Th cell deficiencies. More recently, non-depleting anti-CD4 antibodies also have been evaluated. Here the “coating” efficiency of CD4+ Th cells with the drug seems to be important for suppression suggesting that anti-CD4 antibodies might be able to block Th cell interaction with APCs via a mechanism of steric hindrance. Drastic systemic side effects were not described. However, after encouraging results in early open studies, randomised double blind trials still have to prove efficacy of anti-CD4 therapy or other T-cell directed antibody therapies in RA.

For all the treatments based on the systemic targeting of the whole CD4+ Th cell pool one has to consider that they might also interfere with and eliminate regulatory Th cells, not only those that arise naturally as Treg cells but also those that are generated during immune responses.

**TARGETING B CELLS AND PLASMA CELLS IN AUTOIMMUNITY**

B cells play a variety of pathogenic roles in human autoimmune diseases. On the one hand they may serve as potent autoantigen presenting cells and on the other hand after differentiation into plasma cells they secrete autoantibodies that through complexing antigen can promote local inflammatory reactions. Moreover, certain autoantibodies by themselves can induce direct pathogenesis, such as antithyroid stimulating hormone antibodies in Graves’ disease, antiacetylcholine receptor antibodies in myasthenia gravis, or antineutrophil antibodies in autoimmune neutropenia. Frequently it can be observed that certain autoantibody titres are relatively resistant despite immunosuppressive therapy with high dose steroids or even with cytotoxic drugs such as cyclophosphamide. In particular, antiphospholipid antibodies in primary antiphospholipid syndrome or anti-dsDNA in SLE can be relatively refractory to immunosuppressive therapy. The underlying mechanisms for this phenomenon have been ambiguous for a long time. Although the plasma cell source of such autoantibodies is not well characterised in humans, various experimental studies suggest that long lived autoimmune plasma cells also exist in humans and contribute to the production of pathogenic autoantibodies. However, despite the fact that plasma cells downregulate CD20 during maturation, rituximab therapy in patients with RA modulates autoantibody titres as IgG rheumatoid factor and anticitrullinated peptide antibody levels are significantly reduced while antitetanus toxic IgG is only little influenced. Hence, the exact cellular source (long lived CD20+ plasma cells or short lived CD20+ plasma cells) of individual autoantibodies in various autoimmune diseases is still a black box. It has been hypothesised that particularly in RA B cells may serve as potent local APCs at the site of inflammation. In this case therapeutic B cell depletion with anti-CD20 removes an essential component of the autoimmune reaction that sustains the chronic inflammation leading to a reduction in autoantibody titres (fig 4).

**IMMUNOLOGICAL MEMORY FOR CYTOKINES AND ANTIBodies—THERAPEUTIC CHALLENGES**

A major challenge for effective treatment of human autoimmune diseases has always been the modulation of the effector cells involved in the autoimmune reaction.
Regardless of whether humoral or cellular autoimmunity are the major players, effector cells in both arms of the immune reactions are refractory to many methods of external modulation once they have been activated by cognate interaction. Effector Th cells for instance possess a “cytokine memory”. Once educated in a proper way to produce either inflammatory mediators (interferon $\gamma$) or Th2 cytokines (interleukin (IL)-4, IL-13) they are able to recall their initial cytokine programmes upon re-encounter with antigen. It is the stability of their epigenetic programmes that leads to limited access of gene specific transcription factors to further orchestrate expression of target effector genes. Yet, many factors in these epigenetic regulatory networks remain to be identified. The attempt to shift “cytokine imbalances” in autoimmune diseases using systemic or local administration of anti-inflammatory cytokines, such as IL-4, failed to show efficacy since they are not able to target and modulate the inflammatory effector arm of the Th cell compartment that drives the chronic autoimmune reaction. Moreover, effector Th cells as mentioned above are less sensitive to treatments blocking costimulatory molecules as CTLA4-Ig.

While it is still not clear whether and how effector Th cells become long lived tissue tropic memory Th cells, memory B cells unequivocally differentiate into plasma cells. Some of the effector type B cells are short lived, but an important fraction of plasma cells have been shown to be long lived. Most importantly these plasma cells do not divide and are thus refractory per se to drugs interfering with proliferation of cells. Recently, the role of long lived plasma cells in autoimmune reactions has been further clarified by data from experimental models of SLE. We have shown that a considerable high fraction of plasma cells developing in the spleens of autoimmune NZB/NZW mice are long lived. More importantly we demonstrated that treatment solely with cytotoxic drugs such as cyclophosphamide was unable to target this compartment of long lived plasma cells efficiently while other splenic cell types were easily affected. Treatment refractory autoantibody production has also been quite frequently described in humans. Thus as long as no specific modulation of long lived plasma cells is possible many treatments might spare the humoral effector arm of the autoimmune reaction. It is clear, however, that in case plasma cell specific treatments become feasible protective antibody titres will also be affected. Treatment refractory autoantibody production has also been quite frequently described in humans. Thus as long as no specific modulation of long lived plasma cells is possible many treatments might spare the humoral effector arm of the autoimmune reaction. It is clear, however, that in case plasma cell specific treatments become feasible protective antibody titres will also be affected. Future developments might also target the homing of newly developed plasma blasts that circulate in the peripheral blood into their final survival compartments, such as bone marrow or local sites of inflammation. While the phenotype of such peripheral plasma cells has recently been assessed and various chemokines involved in plasmablast migration have been...
described, plasma cell specific migratory or homing mechanisms have yet to be evaluated in more detail.\(^{24}\)

**COMPLETE IMMUNOAABATION — SUCCESSFUL BUT RISKY**

The most drastic way to achieve maximal treatment efficiency in autoimmune diseases is complete immunoablation. Originally evaluated in experimentally induced autoimmune and found by chance in patients with autoimmune diseases treated with intense immunoablation and HSCT for malignancies it has become evident that high dose treatment might offer an exclusive perspective to cure autoimmune diseases.\(^{29}\) At first, single case reports were presented and subsequently small cohorts of autoimmune patients were enrolled in single centre studies in Chicago, Leiden, and Berlin.\(^{30–32}\) Until 2004, European and international organisations collected data of several hundred cases worldwide where high dose immunosuppression combined with a subsequent HSCT was used for treatment of various autoimmune diseases. Although the numbers sound impressive, comparable clinical study designs were employed in only a minor fraction of these cases.

What have we learned from the now more than five years’ experience in HSCT for autoimmune diseases? What already has been suggested in experimental animal models has been confirmed: even severe systemic autoimmune is curable. However, in the setting of autologous HSCT, autoreactive and thereby pathogenic cells have to be targeted in vivo and also eliminated efficiently from the graft (fig 5). Today, long term remission lasting for more than six years without any treatment has been reported from different centres in particular for patients with treatment refractory SLE. Currently such results cannot be achieved with standard therapies. However, the same studies have also emphasised the major limitation of HSCT in autoimmune patients—that is, a considerable amount of treatment related complications have been reported. Therefore, even though most centres applied stringent inclusion criteria and also took extensive precautions during therapy, treatment related mortality has been reported. Obviously, at the moment HSCT is a treatment option for autoimmune diseases refractory to standard therapies.

A major finding of our studies has been that in patients responding with long term remission a drastic reactivation of thymic activity could be observed. Interestingly, such thymus driven re-establishment of a new polyclonal T cell repertoire was evident even in older patients (age >40 years at transplantation) and was a rather stable than short term phenomenon after HSCT. We assessed frequencies and absolute counts of peripheral blood CD31+ “thymic” naive Th cells as direct markers for thymic activity\(^{34}\) in the course of the patients’ immune reconstitution after HSCT. In all responding patients supranormal levels of “thymic” naive Th cells were detected even four years after HSCT (unpublished results). At the moment we can only hypothesise that a successful “thymic take” and a subsequent stable thymus dependent resetting of a new peripheral Th cell pool is highly predictive for long term remission in autoimmune patients undergoing HSCT. However, it can be foreseen that an adequate quantity of thymus derived natural Treg cells is one of the essential factors for a considerable stable restoration of peripheral tolerance for autoantigens. From numerous reports in experimental animal models it is now clear that CD25++ Tregs efficiently control the immune system potential to self-antigens, although further studies have to be undertaken to clarify the role of Treg in human autoimmune diseases.

Current HSCT study designs are not able to exclude severe side effects. Future developments for HSCT should therefore concentrate on further increasing the specificity of the immunoablation for effector T and B cells as the presently used reagent, ATG or ALG, non-specifically targets almost all leucocyte populations. Another strategy to reduce the cytotoxicity of HSCT is to isolate and preserve pathogen specific T cells from the patient prior to immunoablation to sustain protective immunity afterwards with specific adoptive T cell reinfusion. This at least should be possible in the nearby future for dominant virus pathogens as cytomegalovirus and Epstein–Barr virus. Lastly, the isolation of naive, antigen inexperienced lymphocytes (both B and T cells) prior to immunoablation might be feasible.

**ADOPTIVE TRANSFER OR IN vivo GENERATION OF REGULATORY T CELLS**

As mentioned above, autoreactive Th cells are the main cell type that orchestrate pathogenic autoimmunity in many autoimmune diseases. In a healthy immune system autoreactive Th cells are also present but specialised types of natural and induced regulatory Th cells control and suppress their activities.\(^{35}\) The underlying mechanisms represent the...
The most natural way to treat autoimmunity and thus their use in therapies has been envisaged for quite some time.

A different line of protection in a healthy immune system is guaranteed by tolerogenic APCs. It has been demonstrated that—for example, immature dendritic cells are able to induce the in vitro generation of regulatory Th cells characterised by IL-10 secretion (Tr 1 cells). On a similar basis the immune system tolerises itself in reactions against antigens taken up via mucosal routes. Here transforming growth factor \( \beta \) (TGF\( \beta \)) secreting Th 3 cells are induced. Both the natural ways of protection against unwanted autoimmune reactions would represent ideal therapeutic tools. While their basis is (auto)antigen specificity no systemic side effects have to be expected. Only the action of pathogenic (auto)antigen specific Th cells is modulated and often efficiently suppressed. While it might be not feasible to modulate an established autoimmune reaction by induction of oral tolerance specific for autoantigens as has been hypothesised, the adoptive transfer of ex vivo isolated or induced and in vitro expanded autoantigen specific regulatory Th cells may indeed efficiently target and suppress established chronic inflammation. In experimental animal models at least, such potential of Treg has been demonstrated.

Both the natural ways of protection against unwanted autoimmune reactions would represent ideal therapeutic tools. While their basis is (auto)antigen specificity no systemic side effects have to be expected. Only the action of pathogenic (auto)antigen specific Th cells is modulated and often efficiently suppressed. While it might be not feasible to modulate an established autoimmune reaction by induction of oral tolerance specific for autoantigens (fig 6A) as has been hypothesised, the adoptive transfer of ex vivo isolated or induced and in vitro expanded autoantigen specific regulatory Th cells may indeed efficiently target and suppress established chronic inflammation (fig 6B). In experimental animal models at least, such potential of Treg has been demonstrated.

The greatest therapeutic advantage of Tregs has so far been the biggest limitation for their widespread use in treatment of human autoimmune diseases. Regulatory T cells or Tregs are antigen specific. However, in most human autoimmune diseases various candidate autoantigens have been characterised, but in fact often these may not represent the main targets of the inflammatory autoimmune response. This problem has been recognised and therefore a lot of effort is still being made to identify and characterise new “dominant” autoantigens. Furthermore, it has been suggested that regulatory T cells might not necessarily target the major self-antigen in an autoimmune inflammation. As soon as they are activated at the site of inflammation they exert their action non-specifically (but locally). Such bystander mechanism might work in the case of IL-10 secreting Tr 1 cells as well as for CD25++ Tregs, where the mode of suppression has yet to be characterised.

**TARGETED CELL THERAPY—A REALISTIC PERSPECTIVE?**

Yes, cell therapy of rheumatic diseases needs new concepts to become a true alternative to conventional therapies. Although still a vision, the combination of targeted deletion of autoreactive cells, identified according to their specificity, with the therapeutic resetting of peripheral and central tolerance mechanisms will provide a cure for rheumatic autoimmune diseases in the near future.

**ACKNOWLEDGEMENT**

We thank Dr B Oppmann for critical reading.

**Authors’ affiliations**

A Radbruch, Cell Biology, German Rheumatism Research Centre Berlin, Berlin, Germany

A Thiel, Clinical Immunology, German Rheumatism Research Centre Berlin, Germany

This work was supported by a grant from the ‘BMBF’ (01GI9944/DRFZ C4.1).

Correspondence to: A Radbruch, German Rheumatism Research Centre Berlin, Schumannstr. 21/22, 10117 Berlin, Germany; radbruch@drfz.de
REFERENCES

Cell therapy for autoimmune diseases: does it have a future?

A Radbruch and A Thiel

*Ann Rheum Dis* 2004 63: ii96-ii101
doi: 10.1136/ard.2004.028340

Updated information and services can be found at:
http://ard.bmj.com/content/63/suppl_2/ii96

These include:

**References**

This article cites 39 articles, 11 of which you can access for free at:
http://ard.bmj.com/content/63/suppl_2/ii96#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/